Thread: Coronavirus
View Single Post
Old 23-05-2021, 10:34   #5256
Hugh
laeva recumbens anguis
Cable Forum Team
 
Hugh's Avatar
 
Join Date: Jun 2006
Age: 68
Services: Premiere Collection
Posts: 43,621
Hugh has a golden auraHugh has a golden auraHugh has a golden aura
Hugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden aura
Re: Coronavirus

Quote:
Originally Posted by jfman View Post
I’m aware that this data set wasn’t available then, however there were no shortage of attempts at providing good news stories. Some purporting to show efficacy figures in the 70s and higher after one dose during February and March that I was naturally cynical about.
Not the "popular press", from 5th February.

https://www.sciencemediacentre.org/e...of-sars-cov-2/

Quote:
Prof Deborah Dunn-Walters, Chair of the British Society for Immunology COVID-19 and Immunology Taskforce, and Professor of Immunology at the University of Surrey, said:

The new pre-print published today presents data on how efficient the vaccine is against SARS-CoV-2 infection. It suggests that the AstraZeneca/Oxford vaccine reduces viral load, and the length of time that infected people can carry the virus. Moreover, it shows a similar level of effectiveness against symptomatic disease caused by the new UK variant of SARS-CoV-2 (called B.1.1.7) as it has shown against the previously circulating variant. With cases from the B.1.1.7 virus variant occurring at a high rate in the UK, this initial report can provide reassurance that the AstraZeneca/Oxford vaccine can still provide similar levels of protection against the new circulating virus variant.
Quote:
Dr Gillies O’Bryan-Tear, Past Chair, Policy and Communications, Faculty of Pharmaceutical Medicine, said:

“Genome sequence analysis of a subset of both symptomatic and asymptomatic Covid cases from the Oxford vaccine study, during which the ‘E Kent’ variant B.1.1.7 became more frequent (reaching 28% of the symptomatic cases), showed that clinical efficacy against the new variant was similar for both variants, though the point estimate was slightly lower against the new variant (74% vs 84%), with overlapping confidence intervals meaning that the results are indistinguishable statistically
__________________
Thank you for calling the Abyss.
If you have called to scream, please press 1 to be transferred to the Void, or press 2 to begin your stare.

If my post is in bold and this colour, it's a Moderator Request.
Hugh is offline